In a 2021 experiment that explored the effects of empagliflozin and gemigliptin (a DPP-4 inhibitor used to treat diabetes) on macrophage inflammatory responses, it was discovered that empagliflozin exhibited anti-inflammatory properties. Here, DPP4 is linked to diabetes mellitus.